Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kura Oncology

5.89
-0.2800-4.54%
Post-market: 5.890.00000.00%19:37 EDT
Volume:1.45M
Turnover:8.57M
Market Cap:475.65M
PE:-2.92
High:6.16
Open:6.08
Low:5.82
Close:6.17
Loading ...

Company Profile

Company Name:
Kura Oncology
Exchange:
NASDAQ
Establishment Date:
2014
Employees:
192
Office Location:
12730 High Bluff Drive,Suite 400,San Diego,California,United States
Zip Code:
92130
Fax:
- -
Introduction:
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Directors

Name
Position
Troy Wilson
President and Chief Executive Officer, Chairman
Faheem Hasnain
Director
Robert E. Hoffman
Director
Steven H. Stein
Director
Thomas Malley
Director

Shareholders

Name
Position
Troy Wilson
President and Chief Executive Officer, Chairman
Annette North
Senior Vice President, General Counsel
Heidi Henson
Chief Financial Officer and Secretary
Pingda Ren
Senior Vice President, Chemistry and Pharmaceutical Sciences
Antonio Gualberto
Chief Medical Officer
Yi Liu
Chief Scientific Officer